Treating Lipid Abnormalities Beyond LDL - Washington Hospital ...

More documents

Recommendations

Info

CETP Inhibitors CETP Torcetrapib Dalcetrapib Anacetrapib http://www.ama-assn.org/ama1/pub/upload/mm/365/dalcetrapib.doc; Qiu et al. Nat Struct Mol Biol. 2007;14:106–112.; 2ttp://www.ama-assn.org/ama1/pub/upload/mm/ 365/torcetrapib.doc; http:// www.ama-assn.org/ama1/pub/upload/mm/365/anacetrapib.pdf.; Barter P,et al. N Engl J Med. 2007;357:2109–2122. F F F F F F F F F N o o o F 56
LDL (mg/dL) Define Trial: Effect of Anacetrapib on Plasma HDL and LDL 110 100 90 80 70 60 50 40 30 20 10 0 Decrease LDL = 40% 6 12 18 24 30 46 62 76 Baseline Week Anacetrapib Placebo 110 100 90 80 70 60 No. at Risk Anacetrapib 804 771756 716 687 646 604 568 540 Placebo 803 759759 741 743 735 711 691 666 HDL (mg/dL) 50 40 30 20 10 0 Increase HDL = 138% 6 12 18 24 30 46 62 76 Baseline Week No. at Risk Anacetrapib 807 776757 718 687 647 607 572 543 Placebo 804 766761 741 744 736 711 691 666 Cannon CP, et al. N Engl J Med. 2010;363(25):2406‐2415. Copyright © 2010 Massachusetts Medical Society.
Page 1 and 2:
Treating Lipid Abnormalities Beyond
Page 3 and 4:
THE PYRAMID OF CVD TRIALS Very high
Page 5 and 6: UNMET CLINICAL NEED TREATMENT OF TH
Page 7 and 8: Lipoprotein Metabolism in Patients
Page 9 and 10: LOW HDL-C AS A RESIDUAL RISK FACTOR
Page 11 and 12: THE BEGINNING …
Page 13 and 14: THE RESULT… OF THE SUPER SIZED LI
Page 15 and 16: Current Insights into the Mechanism
Page 17 and 18: Lipid Poor ApoA-I and αHDL αHDL i
Page 19 and 20: Intestine ApoA-I Current Model of H
Page 21 and 22: COLLAR-INDUCED CHANGES IN ENDOTHELI
Page 27 and 28: Potential Mechanisms Involved in th
Page 29 and 30: Increasing HDL By Infusion of HDL,
Page 31 and 32: HDL Targeted Therapies: Niacin 1. D
Page 33 and 34: HATS: Angiographic and Clinical End
Page 35 and 36: � � Aim High randomized 3414 pa
Page 37 and 38: Change in IVUS Total Atheroma Volum
Page 39 and 40: Future HDL Targeted Therapies 1. Pr
Page 41 and 42: Preβ-HDL Infusion Reduced Arterial
Page 43 and 44: Preβ-HDL Enriched Plasma Obtained
Page 45 and 46: The Reduction in Plaque was Greater
Page 47 and 48: Intestine ApoA-I Lipoprotein Profil
Page 49 and 50: 10 mg 30 mg 60 mg Plasma HDLC and L
Page 51 and 52: ILLUMINATE: Investigation of Lipid
Page 53 and 54: CETP Inhibitors CETP Torcetrapib Da
Page 55: The dal-HEART Program: Dalcetrapib
Page 59: FUTURE THERAPY FOR CARDIOVASCULAR D
show all

Treating Lipid Abnormalities Beyond LDL - Washington Hospital ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?